B-cell Non Hodgkin Lymphoma Clinical Trial
Official title:
An Open-label, Single-arm, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AT101 (Anti-CD19 Chimeric Antigen Receptor T Cell) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.
Determine the maximum tolerant dose (MTD) based on the safety and tolerability of AT101 and the recommended dose 2 dose (RP2D) in phase 2 trials for patients with recurrent or non-reactive B cell non-Hodgkin lymphoma (B-cell NHL). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04836195 -
Phase I Trial of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
|
Phase 1 | |
| Active, not recruiting |
NCT04088890 -
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT05472558 -
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
|
Phase 1 | |
| Recruiting |
NCT04191941 -
Treatment of Hematological Malignancy With Novel CAR-T Cells.
|
Early Phase 1 | |
| Active, not recruiting |
NCT04148430 -
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
|
Phase 2 | |
| Recruiting |
NCT05702853 -
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05991388 -
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04887012 -
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
|
Phase 1 | |
| Completed |
NCT04030195 -
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04594642 -
A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05164770 -
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
|
Phase 3 | |
| Completed |
NCT05260203 -
MargheRITA (Remote Intelligence for Therapeutic Adherence)
|
N/A | |
| Active, not recruiting |
NCT05094206 -
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT06392477 -
A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT04412174 -
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
|
Early Phase 1 | |
| Completed |
NCT04748185 -
Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies
|
||
| Active, not recruiting |
NCT03283137 -
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
|
Phase 1 | |
| Completed |
NCT02910063 -
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05744037 -
Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells
|
Phase 2 |